Caspase-3 over-expression is associated with poor overall survival and clinicopathological parameters in breast cancer: a meta-analysis of 3091 cases

Abstract

Caspase-3 is a vital executioner molecule during the apoptotic process. Numerous studies have revealed the close association of caspase-3 expression and breast cancer. Nevertheless, the prognostic value of caspase-3 expression for patients with breast cancer remains uncertain. To thoroughly analyze the prognostic effect of caspase-3 expression on the clinicopathological features and survival of breast cancer, we conducted this meta-analysis. With various search strategies, electronic databases were comprehensively searched. A total of 3091 patients from 21 studies were ultimately obtained. The analysis results indicated that increased expression of caspase-3 had a negative influence on the overall survival (OS) of breast cancer (HR = 1.73, 95%CI 1.12–2.67, P = 0.014). Subgroup analyses based on race revealed that the value of caspase-3 for evaluating patients’ OS was more useful in Asian patients (HR = 3.16, 95%CI 1.20–8.15, P = 0.020), and subgroup analyses based on study analytical methods revealed that caspase-3 was a risk factor for breast cancer patients in multivariate overall survival analyses (HR = 1.67, 95%CI 1.02–2.75, P = 0.044). As for the relationship between caspase-3 expression and breast cancer subtype as well as progression, caspase-3 might serve as a risk factor for the progestogen receptor (PR) and human epidermal growth factor receptor-2 (HER-2) subtypes (OR = 1.44, 95%CI 1.09–1.89, P = 0.010; OR = 1.76, 95%CI 1.18–2.62, P = 0.050, respectively) of breast cancer. However, no evidence showed that increased expression of caspase-3 was statistically correlated with tumor differentiation state (low/moderate or high), tumor TNM stage (I-II/III-IV) or lymph node metastasis (–/+). In conclusion, this meta-analysis revealed that increased caspase-3 expression was significantly associated with worse prognosis and two subtypes of breast cancer. More prospective studies are urgently needed to define the prognostic value of caspase-3 expression in patients with breast cancer.

Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights

“…Caspase 3 (and its cleavage CC3) is the central member of the caspase family, which is cleaved into 29-and 85-kDa fragments by PARP-1 during the early stages of apoptosis, mediating tumour repopulation in apoptotic tumour cells 103 . Recent studies have revealed the close association of caspase 3 expression and breast cancer where a disease with lower or absent apoptosis index has a bad prognosis 55,103 . The caspase 3/9 activation was associated with inhibited cell proliferation, induced apoptosis, as well as increased BAX protein expression in prostate cancer 31,104 .…”

Akt1 and dCIZ1 promote cell survival from apoptotic caspase activation during regeneration and oncogenic overgrowth

“…One hallmark of cancer is the capacity to evade cell death. An apparent paradox is that caspase activity is prevalent in gastric and breast cancers, melanoma, and lymphoma [50][51][52] , amongst others. In recent years, apoptosis and caspases have been shown to promote tumor growth, recurrence, and metastasis both autonomously and non-autonomously 36,[53][54][55][56][57] .…”

Novel roles of apoptotic caspases in tumor repopulation, epigenetic reprogramming, carcinogenesis, and beyond

“…There is increasing evidence that apoptotic caspases are closely associated with cancer progression. A recent meta-analysis revealed that increased caspase 3 expression was statistically correlated with worse prognosis of breast cancer [54]. Zhou et al provided direct experimental evidence in support of a pro-metastatic role of caspases by demonstrating that colon cancer cells with CASP3 knockout were markedly less invasive and more sensitive to radiotherapy in vitro and in vivo .…”